Defining potential to benefit from implantable cardioverter defibrillator therapy: The role of biomarkers

Europace

Volumn 13, Issue 10, 2011, Pages 1419-1427

  Scott, Paul A ^a,b   Townsend, Paul A ^b   Ng, Leong L ^c   Zeb, Mehmood ^a,b   Harris, Scott ^b   Roderick, Paul J ^b   Curzen, Nick P ^a,b   Morgan, John M ^a,b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

Arrhythmias; Biomarkers; Heart failure; Implantable cardioverter defibrillators; Mortality

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 6; SOLUBLE ST2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVERSION; DEFIBRILLATION; DEFIBRILLATOR; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HIGH RISK PATIENT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SUDDEN DEATH; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; RISK FACTORS; TREATMENT OUTCOME;

EID: 80053422909     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur147     Document Type: Article

References (21)

1. Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA III, Freedman RA, Gettes LS et al. ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm 2008;5:934-55.
2. Germano JJ, Reynolds M, Essebag V, Josephson ME. Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic? Am J Cardiol 2006;97:1255-61.
3. Cuculich PS, Sanchez JM, Kerzner R, Greenberg SL, Sengupta J, Chen J et al. Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death. Pacing Clin Electrophysiol 2007;30:207-13. (Pubitemid 46333676)
4. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H et al. Risk Stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008;51:288-96.
5. Braunwald E. Biomarkers in Heart failure. N Engl J Med 2008;358:2148-59.
6. Scott PA, Barry J, Roberts PR, Morgan JM. Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis. Eur J Heart Fail 2009;11:958-66.
7. Kanoupakis EM, Manios EG, Kallergis EM, Mavrakis HE, Goudis CA, Saloustros IG et al. Serum markers of collagen turnover predict future shocks in implantable cardioverter-defibrillator recipients with dilated cardiomyopathy on optimal treatment. J Am Coll Cardiol 2010;55:2753-9.
8. Streitner F, Kuschyk J, Veltmann C, Ratay D, Schoene N, Streitner I et al. Role of proinflammatory markers and NT-proBNP in patients with an implantable cardioverter-defibrillator and an electrical storm. Cytokine 2009;47:166-72.
9. Khan SQ, Ng K, Dhillon O, Kelly D, Quinn P, Squire IB et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J 2009;30:1057-65.
10. Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL, Vázquez R, Puig T, Valdés M et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009;54:2174-9.
11. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005;112:1428-34. (Pubitemid 41291768)
12. Ng LL, Pathik B, Loke IW, Squire IB, Davies JE. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J 2006;152:94-101. (Pubitemid 43974728)
13. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982;69:239-41.
14. Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW et al. Strategic programming of detection and therapy parameters in implantable cardioverterdefibrillators reduces shocks in primary prevention patients: results From the PREPARE (Primary Prevention Parameters Evaluation) Study. J Am Coll Cardiol 2008;52:541-50.
15. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 2008;52:1111-21.
16. Mozaffarian D, Anker SD, Anand I, Linker DT, Sullivan MD, Cleland JG et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation 2007;116:392-8. (Pubitemid 47196544)
17. Pellegrini CN, Lee K, Olgin JE, Turakhia MP, Tseng ZH, Lee R et al. Impact of advanced age on survival in patients with implantable cardioverter defibrillators. Europace 2008;10:1296-1301.
18. Levy WC, Lee KL, Hellkamp AS, Poole JE, Mozaffarian D, Linker DT et al. Maximizing Survival Benefit With Primary Prevention Implantable Cardioverter-Defibrillator Therapy in a Heart Failure population. Circulation 2009;120:835-42.
19. Verma A, Kilicaslan F, Martin DO, Minor S, Starling R, Marrouche NF et al. Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies. Heart 2006;92:190-5. (Pubitemid 43131958)
20. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;29:2388-442.
21. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83. (Pubitemid 34984635)